ArticleJournal of medical case reports2025
Identification of two previously unreported Duchenne muscular dystrophy gene variants in a patient diagnosed with a dystrophinopathy: a case report.
Article in Journal of medical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Molecular Insights and Orthopedic Management in Muscular Dystrophies: A Comprehensive Review.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionDuchenne muscular dystrophy and Becker muscular dystrophy are X-linked recessive disorders affecting muscle function, which are caused by mutations in the dystrophin gene (also known as the Duchenne muscular dystrophy gene). The resulting condition is dictated by the severity of the involved mutation; for instance, Duchenne muscular dystrophy presents in early childhood with rapid progression, whereas Becker muscular dystrophy exhibits a milder, later onset with slower progression. In this report, we present the case of a young patient with clinical symptoms of a dystrophinopathy, whose genetic analysis yielded two previously undescribed mutations within the dystrophin gene. CASE PRESENTATION: This paper focuses on a 12-year-old Syrian male patient with a 6-year history of progressive gait difficulty, lower limb weakness, and recurrent falls. Physical examination revealed a positive Gowers' sign and pseudohypertrophy, but normal muscle strength. A diagnosis of myopathy was supported by elevated serum creatine kinase and a muscle biopsy showing dystrophic changes in the right quadriceps muscle. While the initial deletion and duplication screening in the Duchenne muscular dystrophy gene using multiplex ligation-dependent probe amplification was negative, further extensive genetic analysis revealed two novel hemizygous variants of uncertain significance in the Duchenne muscular dystrophy gene (c.536A > T p.(Asp179Val) and c.680C > T p.(Ser227Phe), with no other clinically relevant variants in the neuromuscular panel.
conclusionThe identification of novel variants in the Duchenne muscular dystrophy gene, alongside the absence of pathogenic mutations in other genes investigated by the neuromuscular panel, strongly suggests an X-linked dystrophinopathy diagnosis in our patient. This case highlights the need for continued exploration of dystrophinopathies' genetic variants. Further studies are required to elucidate the functional impact of these novel variants and to improve our understanding of the genotypic and phenotypic variability observed in these disorders, which may lead to a revolution in treatment approaches and potentially offer curative options for patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.